CLINICAL TRIAL / NCT03269136

Inclusion Criteria: - Relapsed/refractory multiple myeloma - Progressed or are intolerant of established therapies including proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody - Performance Status of 0- 1 ( Performance Score 2 is permitted only if due to underlying myeloma) - Adequate bone marrow, hematological, kidney and liver function - Resolved acute effects of any prior therapy to baseline severity - Not pregnant Exclusion Criteria: - Recent history of other malignancies - History of active autoimmune disorders - Any form of primary immunodeficiency - Active and clinically significant bacterial, fungal, or viral infection - Evidence of active mucosal or internal bleeding - History of severe immune-mediated adverse event with prior immunomodulatory treatment - Major surgery within 4 weeks of study treatment start - Radiation therapy within 2 weeks of study treatment start - History of stem cell transplant (autologous or allogeneic) within 100 days prior to study enrollment - Donor Lymphocyte Infusion (DLI) within 30 days prior to study entry - Less than 30 days since last dose of antibody based therapies or less than 5 half-lives since last dose of previous therapy - Requirement for systemic immune suppressive medication except as permitted in the protocol - Current requirement for chronic blood product support